U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula 2C17H20N2S.C15H12O6
Molecular Weight 857.09
Optical Activity ( + / - )
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROMETHAZINE METHYLENEDISALICYLATE

SMILES

CC(CN1C2=CC=CC=C2SC3=CC=CC=C13)N(C)C.CC(CN4C5=CC=CC=C5SC6=CC=CC=C46)N(C)C.OC(=O)C7=CC(CC8=CC(C(O)=O)=C(O)C=C8)=CC=C7O

InChI

InChIKey=QOLHOCYZKJILAV-UHFFFAOYSA-N
InChI=1S/2C17H20N2S.C15H12O6/c2*1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19;16-12-3-1-8(6-10(12)14(18)19)5-9-2-4-13(17)11(7-9)15(20)21/h2*4-11,13H,12H2,1-3H3;1-4,6-7,16-17H,5H2,(H,18,19)(H,20,21)

HIDE SMILES / InChI

Molecular Formula C15H12O6
Molecular Weight 288.2522
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C17H20N2S
Molecular Weight 284.419
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Promethazine is a phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PROMETHAZINE HYDROCHLORIDE

Approved Use

Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.

Launch Date

2010
Primary
PROMETHAZINE HYDROCHLORIDE

Approved Use

Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.

Launch Date

2010
Primary
PROMETHAZINE HYDROCHLORIDE

Approved Use

Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.

Launch Date

2010
Preventing
PROMETHAZINE HYDROCHLORIDE

Approved Use

Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.

Launch Date

2010
Primary
PROMETHAZINE HYDROCHLORIDE

Approved Use

Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.

Launch Date

2010
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.75 ng/mL
25 mg single, rectal
dose: 25 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9.04 ng/mL
50 mg single, rectal
dose: 50 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
19.3 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
11.28 ng/mL
50 mg single, rectal
dose: 50 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
21.84 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
48.26 ng/mL
50 mg single, intramuscular
dose: 50 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10 ng/mL
12.5 mg single, intravenous
dose: 12.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PROMETHAZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
13.2 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROMETHAZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
146 ng × h/mL
25 mg single, rectal
dose: 25 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
256 ng × h/mL
50 mg single, rectal
dose: 50 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
361 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
146.62 ng × h/mL
50 mg single, rectal
dose: 50 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
180.14 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
627.13 ng × h/mL
50 mg single, intramuscular
dose: 50 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
14466 ng × h/mL
12.5 mg single, intravenous
dose: 12.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PROMETHAZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11511 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROMETHAZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
17.7 h
25 mg single, rectal
dose: 25 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
17.2 h
50 mg single, rectal
dose: 50 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
18.6 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROMETHAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.2 h
12.5 mg single, intravenous
dose: 12.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PROMETHAZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Sources:
unhealthy, 14
Health Status: unhealthy
Age Group: 14
Sex: F
Sources:
Disc. AE: Sinus tachycardia, Consciousness decreased...
AEs leading to
discontinuation/dose reduction:
Sinus tachycardia
Consciousness decreased
Agitation
Confusion
Disorientation
Visual hallucinations
Delirium
Sources:
160 mg single, intramuscular
Highest studied dose
Dose: 160 mg
Route: intramuscular
Route: single
Dose: 160 mg
Sources:
healthy, 21.4±1.7
Health Status: healthy
Age Group: 21.4±1.7
Sex: M+F
Sources:
120 mg single, intramuscular
Higher than recommended
Dose: 120 mg
Route: intramuscular
Route: single
Dose: 120 mg
Sources:
healthy, 22.7±2.31
Health Status: healthy
Age Group: 22.7±2.31
Sex: M+F
Sources:
80 mg 1 times / day multiple, intramuscular
Highest studied dose
Dose: 80 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
healthy, 24.2±1.17
Health Status: healthy
Age Group: 24.2±1.17
Sex: M+F
Sources:
50 mg single, intramuscular|intravenous
Recommended
Dose: 50 mg
Route: intramuscular|intravenous
Route: single
Dose: 50 mg
Sources:
unhealthy
Disc. AE: Respiratory depression, Irritation skin...
AEs leading to
discontinuation/dose reduction:
Respiratory depression (grade 5)
Irritation skin (severe)
Pain
Thrombophlebitis
Sources:
50 mg single, oral
Recommended
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
unhealthy
Disc. AE: Respiratory depression...
AEs leading to
discontinuation/dose reduction:
Respiratory depression (grade 5)
Sources:
AEs

AEs

AESignificanceDosePopulation
Agitation Disc. AE
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Sources:
unhealthy, 14
Health Status: unhealthy
Age Group: 14
Sex: F
Sources:
Confusion Disc. AE
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Sources:
unhealthy, 14
Health Status: unhealthy
Age Group: 14
Sex: F
Sources:
Consciousness decreased Disc. AE
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Sources:
unhealthy, 14
Health Status: unhealthy
Age Group: 14
Sex: F
Sources:
Delirium Disc. AE
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Sources:
unhealthy, 14
Health Status: unhealthy
Age Group: 14
Sex: F
Sources:
Disorientation Disc. AE
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Sources:
unhealthy, 14
Health Status: unhealthy
Age Group: 14
Sex: F
Sources:
Sinus tachycardia Disc. AE
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Sources:
unhealthy, 14
Health Status: unhealthy
Age Group: 14
Sex: F
Sources:
Visual hallucinations Disc. AE
1150 mg single, oral
Overdose
Dose: 1150 mg
Route: oral
Route: single
Dose: 1150 mg
Sources:
unhealthy, 14
Health Status: unhealthy
Age Group: 14
Sex: F
Sources:
Pain Disc. AE
50 mg single, intramuscular|intravenous
Recommended
Dose: 50 mg
Route: intramuscular|intravenous
Route: single
Dose: 50 mg
Sources:
unhealthy
Thrombophlebitis Disc. AE
50 mg single, intramuscular|intravenous
Recommended
Dose: 50 mg
Route: intramuscular|intravenous
Route: single
Dose: 50 mg
Sources:
unhealthy
Respiratory depression grade 5
Disc. AE
50 mg single, intramuscular|intravenous
Recommended
Dose: 50 mg
Route: intramuscular|intravenous
Route: single
Dose: 50 mg
Sources:
unhealthy
Irritation skin severe
Disc. AE
50 mg single, intramuscular|intravenous
Recommended
Dose: 50 mg
Route: intramuscular|intravenous
Route: single
Dose: 50 mg
Sources:
unhealthy
Respiratory depression grade 5
Disc. AE
50 mg single, oral
Recommended
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
unhealthy
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 32 uM]
yes [Inhibition 88 uM]
Drug as victim

Drug as victim

Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Hyperalgesia induced by Asp49 and Lys49 phospholipases A2 from Bothrops asper snake venom: pharmacological mediation and molecular determinants.
2003-05
The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers.
2003-04
Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view.
2003-04
Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
2003-04
Clinical practice. Vestibular neuritis.
2003-03-13
Phenothiazine radicals inactivate Trypanosoma cruzi dihydrolipoamide dehydrogenase: enzyme protection by radical scavengers.
2003-03
Effect of some psychotropic drugs on luminol-dependent chemiluminescence induced by O2-, *OH, HOCl.
2003-02-04
Inactivation of cholinesterase induced by chlorpromazine cation radicals.
2003-02
Effect of phenothiazines on protein kinase C- and calcium-dependent activation of peritoneal macrophages.
2003-02
Interaction between various resistance modifiers and apoptosis inducer 12H-benzo[alpha]phenothiazine.
2003-01-18
Reye's syndrome: down but not out.
2003-01
Interaction of carbamazepine and promethazine in rabbits.
2003-01
In vitro human plasma leucine(5)-enkephalin degradation is inhibited by a select number of drugs with the phenothiazine molecule in their chemical structure.
2003-01
Antiemetic use in pediatric gastroenteritis: a national survey of emergency physicians, pediatricians, and pediatric emergency physicians.
2002-12-05
A systematic approach to the management of postoperative nausea and vomiting.
2002-12
Fibromyositis after intramuscular pentazocine abuse.
2002-11-15
TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms [ISRCTN44153243].
2002-10-16
Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase.
2002-10
Preparation, characterization and taste-masking properties of polyvinylacetal diethylaminoacetate microspheres containing trimebutine.
2002-10
Acute allergic reaction following contact with a spider.
2002-10
Enantioseparation of phenothiazines in cyclodextrin-modified micellar electrokinetic chromatography.
2002-09-20
Project USAP 2000--use of sedative agents by pediatric dentists: a 15-year follow-up survey.
2002-09-06
[Landau-Kleffner and autistic regression: the importance of differential diagnosis].
2002-09
A case of homicide by lethal injection with lidocaine.
2002-09
Recovery, enrichment and selectivity in liquid-phase microextraction comparison with conventional liquid-liquid extraction.
2002-07-19
Bradykinin is involved in hyperalgesia induced by Bothrops jararaca venom.
2002-07
Simultaneous determination of promethazine, chlorpromazine, and perphenazine by multivariate calibration methods and derivative spectrophotometry.
2002-06-27
Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay.
2002-06-19
In vitro reversal of chloroquine resistance in Plasmodium falciparum with dihydroethanoanthracene derivatives.
2002-06
Indirect spectrophotometric determination of propranolol hydrochloride and piroxicam in pure and pharmaceutical formulations.
2002-06
Central effects of cinnarizine: restricted use in aircrew.
2002-06
Next generation antihistamines: therapeutic rationale, accomplishments and advances.
2002-06
Investigation of interaction of promethazine with cyclodextrins.
2002-05-25
Interaction of protonated anticancer thiazines with water-insoluble phospholipids and antineoplastic agents.
2002-05-17
Liquid-phase microextraction of protein-bound drugs under non-equilibrium conditions.
2002-05
Anxiolytic premedication reduces preoperative anxiety and pain during oocyte retrieval. A randomized double-blinded placebo-controlled trial.
2002-05
Study of the stability of promethazine enantiomers by liquid chromatography using a vancomycin-bonded chiral stationary phase.
2002-04-25
Investigation of the effect of tablet surface area/volume on drug release from hydroxypropylmethylcellulose controlled-release matrix tablets.
2002-04
Immunoassay screening of lysergic acid diethylamide (LSD) and its confirmation by HPLC and fluorescence detection following LSD ImmunElute extraction.
2002-04
[Validation of the HPLC method in the determination of dioxopromethazine and phenylephrine in eye drops].
2002-03
Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes.
2002-02
An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers.
2002-01
[A case of fluvoxamine overdose].
2002-01
[The activity of enzymes and free radical oxidation in acute and chronic fetal hypoxia in general anesthesia during cesarean section].
2002
Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity.
2002
[Suicidal attempts with old (currently unused) drug].
2002
Antiallergic anti-inflammatory effects of H1-antihistamines in humans.
2002
Antihistamine antinociception is mediated by Gi-protein activation.
2002
[Work time distribution in night shift: are clinics facing a adjustment boom?].
2001-07
The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare.
2001
Patents

Sample Use Guides

Allergy: the average oral dose is 25 mg taken before retiring; however, 12.5 mg may be taken before meals and on retiring, if necessary. Single 25 mg doses at bedtime or 6.25 to 12.5 mg taken three times daily will usually suffice. After initiation of treatment in children or adults, dosage should be adjusted to the smallest amount adequate to relieve symptoms. The administration of promethazine HCI in 25 mg doses will control minor transfusion reactions of an allergic nature. Motion Sickness: the average adult dose is 25 mg taken twice daily. The initial dose should be taken one-half to one hour before anticipated travel and be repeated 8 to 12 hours later, if necessary. On succeeding days of travel, it is recommended that 25 mg be taken on arising and again before the evening meal. For children, 12.5 to 25 mg, twice daily, may be administered. Nausea and Vomiting: antiemetics should not be used in vomiting of unknown etiology in children and adolescents. The average effective dose of Promethazine HCL Oral Solution for the active therapy of nausea and vomiting in children or adults is 25 mg. When oral medication cannot be tolerated, the dose should be given parenterally or by rectal suppository. 12.5 to 25 mg doses may be repeated, as necessary, at 4 to 6 hour intervals. For nausea and vomiting in children, the usual dose is 0.5 mg per pound of body weight, and the dose should be adjusted to the age and weight of the patient and the severity of the condition being treated. For prophylaxis of nausea and vomiting, as during surgery and the postoperative period, the average dose is 25 mg repeated at 4 to 6 hour intervals, as necessary. Sedation: this product relieves apprehension and induces a quiet sleep from which the patient can be easily aroused. Administration of 12.5 to 25 mg Promethazine HCl Oral Solution by the oral route will provide sedation in children. Adults usually require 25 to 50 mg for nighttime, presurgical, or obstetrical sedation. Pre- and Postoperative Use: promethazine HCl Oral Solution in 12.5 to 25 mg doses for children and 50 mg doses for adults the night before surgery relieves apprehension and produces a quiet sleep. For preoperative medication, children require doses of 0.5 mg per pound of body weight in combination with an appropriately reduced dose of narcotic or barbiturate and the appropriate dose of an atropine-like drug. Usual adult dosage is 50 mg Promethazine HCl Oral Solution with an appropriately reduced dose of narcotic or barbiturate and the required amount of a belladonna alkaloid. Postoperative sedation and adjunctive use with analgesics may be obtained by the administration of 12.5 to 25 mg in children and 25 to 50 mg doses in adults. Promethazine HCL Oral Solution is contraindicated for children under 2 years of age.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:34:10 GMT 2025
Edited
by admin
on Mon Mar 31 21:34:10 GMT 2025
Record UNII
75S19OE56R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PROMETHAZINE METHYLENEDISALICYLATE
JAN  
Common Name English
PROMETHAZINE METHYLENE DISALICYLATE
WHO-DD  
Preferred Name English
PROMETHAZINE METHYLENEDISALICYLATE [JAN]
Common Name English
Promethazine methylene disalicylate [WHO-DD]
Common Name English
(±)-PROMETHAZINE METHYLENEDISALICYLATE
Common Name English
Code System Code Type Description
PUBCHEM
23724861
Created by admin on Mon Mar 31 21:34:10 GMT 2025 , Edited by admin on Mon Mar 31 21:34:10 GMT 2025
PRIMARY
EVMPD
SUB129213
Created by admin on Mon Mar 31 21:34:10 GMT 2025 , Edited by admin on Mon Mar 31 21:34:10 GMT 2025
PRIMARY
SMS_ID
100000155242
Created by admin on Mon Mar 31 21:34:10 GMT 2025 , Edited by admin on Mon Mar 31 21:34:10 GMT 2025
PRIMARY
FDA UNII
75S19OE56R
Created by admin on Mon Mar 31 21:34:10 GMT 2025 , Edited by admin on Mon Mar 31 21:34:10 GMT 2025
PRIMARY
CAS
69376-26-7
Created by admin on Mon Mar 31 21:34:10 GMT 2025 , Edited by admin on Mon Mar 31 21:34:10 GMT 2025
NON-SPECIFIC SUBSTITUTION
EVMPD
SUB04072MIG
Created by admin on Mon Mar 31 21:34:10 GMT 2025 , Edited by admin on Mon Mar 31 21:34:10 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY